 |
| 18-Jan-13 | Reiterated |
MLV & Co |
Buy |
$40 → $21 |
|
| 24-Sep-12 | Reiterated |
Needham |
Buy |
$38 → $32 |
|
| 19-Jul-12 | Reiterated |
MLV & Co |
Buy |
$34 → $40 |
|
| 18-Jul-12 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$39 → $52 |
|
| 18-Jul-12 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 30-Apr-12 | Reiterated |
MLV & Co |
Buy |
$30 → $34 |
|
| 23-Feb-12 | Upgrade |
Rodman & Renshaw |
Mkt Perform → Mkt Outperform |
$39 |
|
| 23-Feb-12 | Upgrade |
Brean Murray |
Sell → Hold |
$2 |
|
| 23-Feb-12 | Reiterated |
MLV & Co |
Buy |
$22 → $30 |
|
| 23-Feb-12 | Reiterated |
JMP Securities |
Mkt Outperform |
$16 → $45 |
|
| 17-Jan-12 | Reiterated |
MLV & Co |
Buy |
$16 → $22 |
|
| 05-Jan-12 | Initiated |
Rodman & Renshaw |
Mkt Perform |
|
|
| 29-Oct-10 | Reiterated |
JMP Securities |
Mkt Outperform |
$12 → $16 |
|
| 03-Aug-10 | Downgrade |
Brean Murray |
Hold → Sell |
$2 |
|
| 16-Jul-10 | Reiterated |
Wedbush |
Outperform |
$20 → $10 |
|
| 16-Jul-10 | Reiterated |
JMP Securities |
Mkt Outperform |
$18 → $12 |
|
| 16-Jul-10 | Downgrade |
Jefferies |
Hold → Underperform |
$9 → $3 |
|
| 16-Jul-10 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 13-Jul-10 | Reiterated |
Brean Murray |
Buy |
$15 → $18 |
|
| 09-Jul-10 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
|
|
| 24-May-13 04:18PM | 3 Humongous Health Care Stocks This Week at Motley Fool |
| 11:02AM | What's behind put trading in Vivus optionMONSTER |
| 11:02AM | What's behind put action in Vivus optionMONSTER |
| 10:27AM | Why This Obesity Drug Is the Sector's Best Bet at Motley Fool |
| 06:20AM | Novo obesity drug could launch in U.S. end 2014 at Reuters |
| 05:41AM | Vivus Heats Up, Shorts Discouraged On Possible Bidding War at Seeking Alpha |
| 02:53AM | Arena - Good Sales, Bad Sales, Long And Short at Seeking Alpha |
| 12:06AM | First Manhattan Still Playing Hardball With Vivus at Seeking Alpha |
| 23-May-13 04:51PM | Denner added as nominee to Vivus board by activist investor at Reuters +7.25% |
| 04:21PM | Bullish Two Hundred Day Moving Average Cross - VVUS at TheStreet |
| 03:26PM | [video] Options Activity Ahead of Pandora Earnings at CNBC |
| 01:55PM | Why This Obesity Drug Is the Sector's Best Bet at Motley Fool |
| 01:02PM | [video] Nasdaq Check: Tech Stocks Recover at CNBC |
| 09:35AM | Alex Denner Joins Vivus Activist Slate in Post-Icahn Move at Bloomberg |
| 06:31AM | InPlay: Vivus: First Manhattan adds Alex Denner to Vivus Board slate; Denner's Sarissa Capital Management owns 2 mln Vivus shares Briefing.com |
| 06:30AM | First Manhattan Adds Alex Denner to Vivus Board Slate Business Wire |
| 22-May-13 08:56PM | 3 Pipeline Obesity Treatments You Should Watch at Motley Fool |
| 07:00AM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 03:19AM | Arena Pharmaceuticals - Out To Launch Or Out To Lunch? at Seeking Alpha |
| 21-May-13 09:06AM | VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o EDGAR Online |
| 06:56AM | The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does at Seeking Alpha |
| 20-May-13 02:06PM | The 9 Most Obese Countries in the World at Motley Fool +5.53% |
| 19-May-13 09:41AM | Vivus Taps Into More Cash at Seeking Alpha |
| 18-May-13 08:01AM | 25 Belt-Busting Obesity Facts at Motley Fool |
| 16-May-13 10:22AM | VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme EDGAR Online |
| 07:02AM | InPlay: Vivus prices offering of $220 mln aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 Briefing.com |
| 07:00AM | VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes GlobeNewswire |
| 15-May-13 07:04PM | Weight Loss Isn't Just for Looking Good Anymore at Motley Fool -5.00% |
| 01:28PM | Is Vivus a Buy at These Prices? at Wall St. Cheat Sheet |
| 01:04PM | VIVUS INC Financials EDGAR Online Financials |
| 11:38AM | Vivus to sell $200 million in convertible debt AP |
| 10:18AM | Vivus - Mild Drama Continues at Seeking Alpha |
| 08:42AM | Will Obesity Drugs Gain Soon? at Motley Fool |
| 07:02AM | InPlay: Vivus announces offering of $200 mln aggregate principal amount of convertible senior unsecured notes due May 1, 2020 Briefing.com |
| 07:00AM | VIVUS Announces Proposed Offering of Convertible Senior Notes GlobeNewswire |
| 12:06AM | VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 14-May-13 02:19PM | Analysts: Market Is Beginning to Recognize Tesla and 3 Other Research Notes to Check Out at Wall St. Cheat Sheet |
| 07:00AM | VIVUS Announces Scientific Presentations GlobeNewswire |
| 05:49AM | Looking at Arena Following Sell-Off at Motley Fool |
| 05:42AM | Vivus Starting To Gain The Advantage Over Arena at Seeking Alpha |
| 01:16AM | Shorting Arena Is Not a Good Idea Now at Motley Fool |
| 01:08AM | Arena, Vivus, And Off-Label Prescriptions at Seeking Alpha |
| 13-May-13 04:18PM | Vivus Adds Two New Directors to Board Amid Pressure at Bloomberg |
| 01:24PM | Vivus Increases Board to 9 Members at Motley Fool |
| 11:28AM | Starbucks Looks to Myanmar, Delta and United Grapple With New Flu, and 2 Other Hot Stocks at Wall St. Cheat Sheet |
| 11:17AM | Vivus names 2 new directors to its board AP |
| 09:33AM | Vivus Adds Two New Directors to Board Amid Pressure at Bloomberg |
| 07:05AM | VIVUS Mails Letter to Stockholders Providing Business Update GlobeNewswire |
| 07:00AM | VIVUS Appoints J. Martin Carroll and Jorge Plutzky, M.D. to Board of Directors GlobeNewswire |
| 12:08AM | VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Ch EDGAR Online |
| 12-May-13 05:34PM | Earnings Volatility Drives These Healthcare Stocks in a New Direction at Wall St. Cheat Sheet |
| 12:30PM | 4 Technologies That Can Help Track Weight Loss at Motley Fool |
| 11-May-13 03:00PM | Deal Discussions Distract From Disappointing Obesity Drug Sales at Motley Fool |
| 09:53AM | Why Does Arena's Obesity Drug Have Abuse Potential? at Forbes |
| 10-May-13 02:31PM | Belviq's Sales Will Disappoint: Demographics Matter at Seeking Alpha |
| 12:34PM | APB Financial Group and Hedge Fund Solutions to Host Webcast to Discuss First Manhattan Co's Activist Investment in VIVUS, Inc. GlobeNewswire |
| 02:07AM | Vivus Shifting Gears at Seeking Alpha |
| 09-May-13 08:16PM | Is the Golden Age of Blockbusters Over? at Motley Fool |
| 03:20PM | ARNA Sheds Light on Belviq Launch Zacks |
| 11:13AM | [video] On the Hunt For Yield at SALT at CNBC |
| 08:35AM | VIVUS Reports Wider Loss Zacks |
| 07:12AM | Obesity Drug Demand Still Low at Motley Fool |
| 08-May-13 11:03PM | VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements and E EDGAR Online +9.72% |
| 09:29PM | 4 Stocks Spiking on Big Volume at TheStreet |
| 08:00PM | These Stocks Sent the Dow Soaring Again at Motley Fool |
| 04:09PM | Vivus Is in Talks With Potential Marketing Partners at Bloomberg |
| 03:10PM | Vivus, Obesity Drug Stocks Finally Get Some Good News at Investor's Business Daily |
| 01:41PM | Will The Prescription Diet Pill Market Finally Bulk Up? at Forbes |
| 12:05PM | Vivus' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 11:54AM | Vivus in Talks With Potential Marketing Partners, CEO Says at Bloomberg |
| 09:30AM | Ahead of the Bell: Vivus 1Q loss widens AP |
| 09:01AM | VIVUS Earnings: Heres Why Investors Dont Like These Results at Wall St. Cheat Sheet |
| 08:54AM | Vivus reports weak sales of diet pill Qsymia at Reuters |
| 07:50AM | Vivus reports weak sales of diet pill Qsymia at Reuters |
| 07:30AM | VIVUS Reports First Quarter 2013 Financial Results GlobeNewswire |
| 07:07AM | Q1 2013 Vivus Inc. Earnings Release - Before Market Open CCBN |
| 12:38AM | VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements and E EDGAR Online |
| 07-May-13 04:18PM | InPlay: Vivus: First Manhattan Co. releases case for full board change at Vivus Briefing.com |
| 04:15PM | First Manhattan Co. Releases Case for Full Board Change at Vivus Business Wire |
| 01:42PM | The Long Wait for This Obesity Drug Is Almost Over at Motley Fool |
| 12:38PM | Arenas FDA-Approved Weight Loss Pill Clears DEA Hurdle at Bloomberg |
| 12:10PM | Improving Prospects of This Obesity Bet at Motley Fool |
| 11:53AM | Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives at TheStreet |
| 08:14AM | Looking For Real Viagra? Head to the Internet. at Motley Fool |
| 07:00AM | VIVUS Announces Richard Fante, Former President U.S. and CEO North America, AstraZeneca, to Serve as Senior Advisor GlobeNewswire |
| 01:25AM | Arena And Vivus Weaken On Poor Obesity Drug Prospects In Europe at Seeking Alpha |
| 12:08AM | VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 06-May-13 08:52PM | This Is Why Doctors Love Apple at Wall St. Cheat Sheet |
| 05-May-13 03:00PM | Are Obesity Drugs a Lost Cause in Europe? at Motley Fool |
| 04-May-13 08:00AM | U.S.-Approved Obesity Drug Derailed in EU at Motley Fool |
| 02-May-13 05:48PM | Arena Falls, Pulls Anti-Obesity Application In Europe at Seeking Alpha |
| 05:12PM | Arena Withdrawing Obesity Drug Regulatory Application in Europe at Bloomberg |
| 01-May-13 03:05PM | First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus Board at the 2013 Annual Meeting Business Wire |
| 11:15AM | Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology Companies Wall Street Transcript |
| 09:11AM | Vivus And Anti-Obesity Sector Benefit From New Insurance Deal at Seeking Alpha |
| 08:34AM | First Manhattan Comments on Addition to Vivus Board of Directors Business Wire |
| 08:13AM | 3 Healthcare Stock Stories For Tuesday Portfolio Wellness at Wall St. Cheat Sheet |
| 07:05AM | VIVUS Announces Date of First Quarter 2013 Financial Results and Conference Call GlobeNewswire |
| 07:01AM | InPlay: Vivus: New guidelines from American Association of Clinical Endocrinologists recommend medical treatment of obesity Briefing.com |
| 07:00AM | New Guidelines From American Association of Clinical Endocrinologists Recommend Medical Treatment of Obesity GlobeNewswire |
|
|
| VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CASAMENTO CHARLES J | Director | Aug 20 | Option Exercise | 5.69 | 8,000 | 45,520 | 74,000 | Aug 21 07:00 PM | | MARIO ERNEST | Director | Aug 20 | Buy | 20.75 | 5,000 | 103,750 | 45,000 | Aug 21 07:03 PM | | CASAMENTO CHARLES J | Director | Aug 20 | Sale | 20.63 | 8,000 | 165,060 | 66,000 | Aug 21 07:00 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 14 | Option Exercise | 4.60 | 18,000 | 82,820 | 15,000 | Aug 15 07:53 PM | | LOGAN MARK B | Director | Aug 14 | Option Exercise | 5.64 | 49,816 | 280,838 | 75,000 | Aug 15 07:54 PM | | LOGAN MARK B | Director | Aug 14 | Sale | 23.13 | 49,816 | 1,152,169 | 53,000 | Aug 15 07:54 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 14 | Sale | 22.72 | 18,000 | 409,000 | 5,000 | Aug 15 07:53 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 13 | Option Exercise | 4.25 | 20,000 | 85,000 | 25,000 | Aug 14 06:47 PM | | LOGAN MARK B | Director | Aug 13 | Option Exercise | 4.25 | 18,184 | 77,282 | 71,184 | Aug 14 06:52 PM | | LOGAN MARK B | Director | Aug 13 | Sale | 21.81 | 18,184 | 396,580 | 53,000 | Aug 14 06:52 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 13 | Sale | 22.00 | 20,000 | 440,000 | 5,000 | Aug 14 06:47 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 10 | Option Exercise | 4.23 | 25,000 | 105,750 | 30,000 | Aug 14 06:47 PM | | MARIO ERNEST | Director | Aug 10 | Buy | 21.50 | 5,000 | 107,500 | 40,000 | Aug 13 06:00 PM | | SHORTLIFFE LINDA M DAIRIKI | Director | Aug 10 | Sale | 21.50 | 25,000 | 537,500 | 5,000 | Aug 14 06:47 PM | | MARIO ERNEST | Director | Aug 09 | Buy | 21.83 | 15,000 | 327,399 | 35,000 | Aug 13 06:00 PM | | Slebir John L | VP, General Counsel | Jul 18 | Option Exercise | 7.27 | 10,000 | 72,713 | 10,376 | Jul 20 07:21 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jul 18 | Option Exercise | 10.19 | 25,000 | 254,750 | 32,943 | Jul 20 07:07 PM | | MARSH GUY P | VP, Operations and General Mgr | Jul 18 | Option Exercise | 4.69 | 36,191 | 169,664 | 25,713 | Jul 20 07:10 PM | | WILSON LELAND F | CEO | Jul 18 | Option Exercise | 3.34 | 100,000 | 333,754 | 169,427 | Jul 20 07:12 PM | | MORRIS TIMOTHY E | VP, Finance and CFO | Jul 18 | Option Exercise | 4.23 | 25,000 | 105,750 | 25,000 | Jul 20 07:14 PM | | TAM PETER Y | President | Jul 18 | Option Exercise | 4.25 | 25,000 | 106,250 | 62,629 | Jul 20 07:17 PM | | TAM PETER Y | President | Jul 18 | Sale | 30.95 | 25,000 | 773,750 | 37,629 | Jul 20 07:17 PM | | MORRIS TIMOTHY E | VP, Finance and CFO | Jul 18 | Sale | 30.36 | 25,000 | 759,000 | 0 | Jul 20 07:14 PM | | WILSON LELAND F | CEO | Jul 18 | Sale | 30.36 | 100,000 | 3,036,000 | 119,112 | Jul 20 07:12 PM | | MARSH GUY P | VP, Operations and General Mgr | Jul 18 | Sale | 30.36 | 36,191 | 1,098,759 | 2,074 | Jul 20 07:10 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jul 18 | Sale | 30.36 | 25,000 | 759,000 | 7,943 | Jul 20 07:07 PM | | Slebir John L | VP, General Counsel | Jul 18 | Sale | 30.36 | 10,000 | 303,600 | 4,126 | Jul 20 07:21 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 27 | Option Exercise | 10.19 | 25,000 | 254,750 | 32,943 | Jun 29 05:01 PM | | WILSON LELAND F | CEO | Jun 27 | Option Exercise | 4.15 | 50,000 | 207,500 | 169,112 | Jul 02 09:49 PM | | WILSON LELAND F | CEO | Jun 27 | Sale | 28.00 | 50,000 | 1,400,000 | 119,112 | Jul 02 09:49 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 27 | Sale | 28.08 | 25,000 | 701,900 | 7,943 | Jun 29 05:01 PM | | TAM PETER Y | President | Jun 19 | Option Exercise | 3.73 | 20,000 | 74,600 | 57,629 | Jun 20 07:29 PM | | TAM PETER Y | President | Jun 19 | Sale | 27.25 | 20,000 | 545,000 | 37,629 | Jun 20 07:29 PM | | TAM PETER Y | President | Jun 18 | Option Exercise | 3.73 | 20,000 | 74,600 | 57,629 | Jun 19 06:42 PM | | TAM PETER Y | President | Jun 18 | Sale | 26.45 | 20,000 | 529,000 | 37,629 | Jun 19 06:42 PM | | TAM PETER Y | President | Jun 14 | Option Exercise | 3.95 | 236,250 | 932,550 | 123,149 | Jun 18 09:24 PM | | TAM PETER Y | President | Jun 14 | Sale | 25.25 | 60,000 | 1,515,000 | 37,629 | Jun 18 09:25 PM | | TAM PETER Y | President | Jun 14 | Sale | 25.28 | 236,250 | 5,973,534 | 97,629 | Jun 18 09:24 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 12 | Option Exercise | 10.19 | 25,000 | 254,750 | 32,943 | Jun 14 05:11 PM | | MILLER MICHAEL PATRICK | Chief Commercial Officer | Jun 12 | Sale | 25.00 | 25,000 | 625,000 | 7,943 | Jun 14 05:11 PM | | WILSON LELAND F | CEO | Jun 11 | Option Exercise | 4.15 | 50,000 | 207,500 | 145,232 | Jun 13 01:11 PM | | WILSON LELAND F | CEO | Jun 11 | Sale | 25.18 | 50,000 | 1,259,000 | 119,112 | Jun 13 01:11 PM |
|
|
|
|
|
|
